Cargando…
Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol
BACKGROUND: This was the first real-world head-to-head study comparing inhaled long-acting muscarinic antagonist/long-acting β(2)-agonist fixed-dose combination treatments as maintenance therapy. METHODS: Retrospective observational study including commercial, Medicare Advantage with Part D or Part...
Autores principales: | Moretz, Chad, Bengtson, Lindsay GS, Sharpsten, Lucie, Koep, Eleena, Le, Lisa, Tong, Junliang, Stanford, Richard H, Hahn, Beth, Ray, Riju |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732570/ https://www.ncbi.nlm.nih.gov/pubmed/31564852 http://dx.doi.org/10.2147/COPD.S213520 |
Ejemplares similares
-
Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study
por: Moretz, Chad, et al.
Publicado: (2019) -
The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models
por: Buikema, Ami R., et al.
Publicado: (2018) -
Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England
por: Requena, Gema, et al.
Publicado: (2023) -
Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol
por: Sethi, Sanjay, et al.
Publicado: (2023) -
Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History
por: Sethi, Sanjay, et al.
Publicado: (2023)